News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

If Arena Pharmaceuticals, Inc. (ARNA)'s Lorcaserin is Approved, Buy VIVUS, Inc. (VVUS)



6/26/2012 7:11:59 AM

There are conflicting messages coming out of recent FDA advisory panels. On March 29, 2012, an Endocrinologic and Metabolic Drugs Advisory Committee voted to require cardiovascular outcome trials (CVOT) using major cardiovascular events (MACE) as the primary endpoint. But on May 10, 2012, another Endocrinologic and Metabolic Drugs Advisory voted 18-4-1 in favor of approval of Arena's (ARNA) obesity drug, Lorcaserin (briefing document for that meeting). The dynamics of the panelists views on the first committee addressing cardiovascular safety of obesity drugs (March 29, 2012) are interesting. The vote was 17-6 in favor of requiring CVOTs for obesity drug approval.

Read at Seeking Alpha
Read at CNBC


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES